Cover Image
Market Research Report

Global Candidiasis Drugs Market 2019-2023

Published by TechNavio (Infiniti Research Ltd.) Product code 781938
Published Content info 124 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Candidiasis Drugs Market 2019-2023
Published: January 23, 2019 Content info: 124 Pages
Description

About this market

Advances in diagnosis of antifungal resistant pathogens to drive market growth. Although the currently available antifungal drugs are killing various species of candidiasis, some fungi can develop the ability to defend these drugs. For instance, Candida auris, an emerging antifungal¬resistant yeast, is frequently resistant to multiple antifungal drugs that were used to treat Candida infections. Moreover, it can cause serious bloodstream infections in hospitalized patients. Hence, advanced technologies are required for the diagnosis of such fungal diseases caused by antifungal¬resistant pathogens. Technavio' s analysts have predicted that the candidiasis drugs market will register a CAGR of almost 4% by 2023.

Market Overview

Rising awareness about candidiasis

The signs and symptoms of candidiasis are very broad, and they also depend on the type of candidiasis infection. They sometimes resemble the symptoms of other diseases caused by bacteria. Hence, confirmatory diagnosis methods are required to confirm the disease after assessing the initial symptoms. Early detection can aid in treating them more effectively. Therefore, to create awareness about the disease and treatment options and avoid delay in diagnosis, the CDC is providing information about candidiasis, and its causes, risk factors, transmission, diagnosis, and treatment in the US.

Side effects of available drugs

Although several off-label medications are available for the symptomatic treatment of candidiasis, the side effects associated with them are decreasing their preference. For instance, polyene antifungal medicine, nystatin causes mouth irritation, diarrhea, nausea, vomiting, stomach upset, rashes, hives, and skin irritation. Although azole medications such as fluconazole, voriconazole, and miconazole are usually well tolerated, they cause side effects such as a headache, nausea, abdominal pain, diarrhea, vomiting, dyspepsia, liver damages, and rashes.

For the detailed list of factors that will drive and challenge the growth of the candidiasis drugs market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Merck and Pfizer the competitive environment is quite intense. Factors such as the advances in diagnosis of antifungal resistant pathogens and the rising awareness about candidiasis, will provide considerable growth opportunities to candidiasis drugs manufactures. Astellas Pharma, Bayer, Fresenius, Merck, and Pfizer are some of the major companies covered in this report.

Table of Contents
Product Code: IRTNTR30727

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Azoles - Market size and forecast 2018-2023
  • Echinocandins - Market size and forecast 2018-2023
  • Other drugs - Market size and forecast 2018-2023
  • Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 10: MARKET TRENDS

PART 11: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 12: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Astellas Pharma
  • Bayer
  • Fresenius
  • Merck
  • Pfizer

PART 13: APPENDIX

  • Research methodology
  • List of abbreviations

List of Exhibits

  • Exhibit 01: Years in consideration
  • Exhibit 02: Global infectious disease treatment market
  • Exhibit 03: Segments of global infectious disease treatment market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Type - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by type
  • Exhibit 20: Azoles - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Azoles - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Echinocandins - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Echinocandins - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Other drugs - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 25: Other drugs - Year-over-year growth 2019-2023 (%)
  • Exhibit 26: Market opportunity by type
  • Exhibit 27: Customer landscape
  • Exhibit 28: Market share by geography 2018-2023 (%)
  • Exhibit 29: Geographic comparison
  • Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Top 3 countries in North America
  • Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: Top 3 countries in Europe
  • Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 38: Top 3 countries in Asia
  • Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 41: Top 3 countries in ROW
  • Exhibit 42: Key leading countries
  • Exhibit 43: Market opportunity
  • Exhibit 44: Decision framework
  • Exhibit 45: Impact of drivers and challenges
  • Exhibit 46: Vendor landscape
  • Exhibit 47: Landscape disruption
  • Exhibit 48: Vendors covered
  • Exhibit 49: Vendor classification
  • Exhibit 50: Market positioning of vendors
  • Exhibit 51: Astellas Pharma - Vendor overview
  • Exhibit 52: Astellas Pharma - Business segments
  • Exhibit 53: Astellas Pharma - Organizational developments
  • Exhibit 54: Astellas Pharma - Geographic focus
  • Exhibit 55: Astellas Pharma - Key offerings
  • Exhibit 56: Astellas Pharma - Key customers
  • Exhibit 57: Bayer - Vendor overview
  • Exhibit 58: Bayer - Business segments
  • Exhibit 59: Bayer - Organizational developments
  • Exhibit 60: Bayer - Geographic focus
  • Exhibit 61: Bayer - Segment focus
  • Exhibit 62: Bayer - Key offerings
  • Exhibit 63: Bayer - Key customers
  • Exhibit 64: Fresenius - Vendor overview
  • Exhibit 65: Fresenius - Business segments
  • Exhibit 66: Fresenius - Organizational developments
  • Exhibit 67: Fresenius - Geographic focus
  • Exhibit 68: Fresenius - Segment focus
  • Exhibit 69: Fresenius - Key offerings
  • Exhibit 70: Fresenius - Key customers
  • Exhibit 71: Merck - Vendor overview
  • Exhibit 72: Merck - Business segments
  • Exhibit 73: Merck - Organizational developments
  • Exhibit 74: Merck - Geographic focus
  • Exhibit 75: Merck - Segment focus
  • Exhibit 76: Merck - Key offerings
  • Exhibit 77: Merck - Key customers
  • Exhibit 78: Pfizer - Vendor overview
  • Exhibit 79: Pfizer - Business segments
  • Exhibit 80: Pfizer - Organizational developments
  • Exhibit 81: Pfizer - Geographic focus
  • Exhibit 82: Pfizer - Segment focus
  • Exhibit 83: Pfizer - Key offerings
  • Exhibit 84: Pfizer - Key customers
  • Exhibit 85: Validation techniques employed for market sizing
  • Exhibit 86: List of abbreviations
Back to Top